The Journal of Experimental Medicine
BioLegend: New Th17, Treg Tools
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online March 24, 2008
doi:10.1084/jem.20071087
The Journal of Experimental Medicine, Vol. 205, No. 4, 869-882
The Rockefeller University Press, 0022-1007 $30.00
© 2008 Kool et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Related biobytes podcast
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Kool, M.
Right arrow Articles by Lambrecht, B. N.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kool, M.
Right arrow Articles by Lambrecht, B. N.
Related Collections
Right arrowRelated In this Issue article
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

ARTICLE

 Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells

Mirjam Kool1, Thomas Soullié1, Menno van Nimwegen1, Monique A.M. Willart1,2, Femke Muskens1, Steffen Jung3, Henk C. Hoogsteden1, Hamida Hammad1,2, and Bart N. Lambrecht1,2

1 Department of Pulmonary Medicine, Erasmus University Medical Centre, 3015 GD Rotterdam, Netherlands
2 Laboratory of Immunoregulation, University Hospital Ghent, 9000 Ghent, Belgium
3 Weizmann Institute, Rehovot 76100, Israel

CORRESPONDENCE Bart N. Lambrecht: bart.lambrecht{at}ugent.be

Alum (aluminum hydroxide) is the most widely used adjuvant in human vaccines, but the mechanism of its adjuvanticity remains unknown. In vitro studies showed no stimulatory effects on dendritic cells (DCs). In the absence of adjuvant, Ag was taken up by lymph node (LN)–resident DCs that acquired soluble Ag via afferent lymphatics, whereas after injection of alum, Ag was taken up, processed, and presented by inflammatory monocytes that migrated from the peritoneum, thus becoming inflammatory DCs that induced a persistent Th2 response. The enhancing effects of alum on both cellular and humoral immunity were completely abolished when CD11c+ monocytes and DCs were conditionally depleted during immunization. Mechanistically, DC-driven responses were abolished in MyD88-deficient mice and after uricase treatment, implying the induction of uric acid. These findings suggest that alum adjuvant is immunogenic by exploiting "nature's adjuvant," the inflammatory DC through induction of the endogenous danger signal uric acid.

Abbreviations used: Ag, antigen; Alum, aluminum hydroxide; CLN, cervical LN; DLN, draining LN; DT, diphteria toxin; DTR, DT receptor; ILN, inguinal LN; i.t., intratracheal; MLN, mediastinal LN; Tg, transgenic.

M. Kool, T. Soullié, H. Hammad, and B.N. Lambrecht contributed equally to this paper.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related In this Issue article

How alum works
Hema Bashyam
J. Exp. Med. 2008 205: 742. [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS